ArticleScientific reports2025
Catechin suppresses HNSC via STXBP1 dependent inhibition of macrophage infiltration and CD47 mediated immune evasion.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Unveiling the impact of interferon genes on the immune microenvironment of triple-negative breast cancer: identification of therapeutic targets.Frontiers in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The treatment of head and neck squamous cell carcinoma (HNSC) faces significant challenges, primarily due to the lack of reliable biomarkers and effective therapeutic drugs. This study reveals the crucial mechanistic role of STXBP1 in the HNSC tumor microenvironment: STXBP1 promotes tumor immune escape through dual pathways, not only enhancing the infiltration of M2-type macrophages but also activating the 'don't eat me' signaling pathway through upregulation of CD47. Clinical data analysis demonstrates that STXBP1 expression levels significantly correlate with HNSC patient prognosis, suggesting its potential as a diagnostic marker and prognostic indicator. Mechanistic studies show that targeted inhibition of STXBP1 effectively downregulates CD47 expression and restores the anti-tumor function of macrophages. Based on bioinformatics screening and experimental validation, we discovered that the natural compound Catechin can specifically inhibit STXBP1 expression and significantly suppress tumor growth. These findings not only elucidate the molecular mechanism of STXBP1 in HNSC but also provide a new candidate drug for clinical treatment, holding significant translational medical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.